Eiken Chemical Co., Ltd. (TYO:4549)

Market Cap	90.36B +22.6%
Revenue (ttm)	41.90B +3.4%
Net Income	3.71B +66.4%
EPS	112.08 +74.4%
Shares Out	32.97M
PE Ratio	24.46
Forward PE	29.83
Dividend	58.00 (2.16%)
Ex-Dividend Date	Mar 30, 2026

Volume	194,100
Open	2,730.00
Previous Close	2,683.00
Day's Range	2,666.00 - 2,755.00
52-Week Range	1,972.00 - 3,500.00
Beta	0.33
Analysts	n/a
Price Target	n/a
Earnings Date	May 12, 2026

About Eiken Chemical

Eiken Chemical Co., Ltd. engages in the manufacture and sale of clinical diagnostics in Japan. It offers microbiological reagents for diagnosis of microorganism infection, such as mediums, antimicrobial susceptibility, and rapid test reagents; urinalysis test strips for occult blood, protein, and glucose; and fecal immunochemical tests reagents for screening of colorectal cancer. The company also provides immunological and serological reagents to detect and monitor infectious disease, rheumatism, inflammation, atrophic gastritis, and prostate s...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1939
• Employees: 702
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4549

Financial Performance

In fiscal year 2026, Eiken Chemical's revenue was 41.90 billion, an increase of 3.35% compared to the previous year's 40.54 billion. Earnings were 3.71 billion, an increase of 66.43%.